Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both

Antiviral Therapy

Volumn 9, Issue 6, 2004, Pages 969-977

  Ballesteros, Àngel Luis ^a   Miró, Òscar ^b   López, Sònia ^b   Fuster, Daniel ^a   Videla, Sebastiá ^a   Martínez, Eva ^a   Garrabou, Glòria ^b   Salas, Anna ^a   Côté, Hélène ^c   Tor, Jordi ^a   Rey Joly, Celestino ^a   Planas, Ramon ^a   Clotet, Bonaventura ^a   Tural, Cristina ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c Centre for Excellence in HIV/AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; MITOCHONDRIAL DNA; PEGINTERFERON ALPHA2B; RIBAVIRIN; STAVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS INFECTION;

ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DIDANOSINE; DNA, MITOCHONDRIAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MITOCHONDRIA; REVERSE TRANSCRIPTASE INHIBITORS; RIBAVIRIN; STAVUDINE; TIME FACTORS;

EID: 19944407445     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiftman M, Reindollar R, Goodman ZD, Koury K, Ling M & Albrecht JK. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J & Yu J. Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 2002; 347:975-982.
3. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T & Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clinical Infections Diseases 2001; 33:562-569.
4. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, Matheron S, Le Moing V, Vachon F, Degott C, Valla D & Marcellin P. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34:1193-1199.
5. Quereda C, Moreno L, Moreno A, Diaz S, Barcena R, Marti-Belda P, Mateos M, Pérez-Elias M, Casado J & Moreno S. Early prediction of response to pegylated interferon-alfa 2b plus ribavirin in patients co-infected with HIV and HCV. 42nd Interscience Conference on Antimicrobial Agents & Chemotherapy. 27-30 September 2002, San Diego, Calif., USA. Abstract H-1724.
6. Perronne C, Carrat F, Banisadr F, Morand P, Lunel F, Roshental E & Pol S. Final results of ANRS HC02-RIBAVIC: A randomised controlled trial of pegylated-interferon alfa-2b plus ribavirin vs interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients. 11th Conference on Retroviruses & Opportunistic Infections. 8-11 February 2004. San Francisco, Calif., USA. Abstract 117LB.
7. Pérez-Olmeda M, Núñez M, Romero M, González J, Castro A, Arribas JR, Pedreira J, Barreiro P, García-Samaniego J, Martín-Carbonero L, Jiménez-Nacher I & Soriano V. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023-1028.
8. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM & Dieterich DT; APRICOT Study Group. Peginterferon alfa 2a plus ribavirin for chronic hepatitis C virus infection in HIV patients. New England Journal of Medicine 2004; 351:438-450.
9. Lafeuillade A, Hittinger G & Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-281.
10. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ & Mallal SA. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15:717-723.
11. Delgado J, Harris M, Tesiorowski A & Montaner J. Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series. Clinical Infectious Diseases 2001; 33:2072-2074.
12. Hartman NR, Ahluwalia GS, Cooney DA, Mitsuya H, Kageyama S, Fridland A, Broder S & Johns DG. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′3′-dideoxyadenosine and 2′3′-dideoxyinosine. Molecular Pharmacology 1991; 40:118-124.
13. Fleischer R, Boxwell D & Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clinical Infectious Diseases 2004; 38:79-80.
14. Côté HCF, Brumme ZL, Craib KJP, Math M, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan R, O'Shaughnessy & Montaner J. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. New England Journal of Medicine 2002; 346:811-820.
15. Casademont J, Miró O & Cardellach F. Mitochondrial DNA and nucleoside toxicity. New England Journal of Medicine 2002; 347:216-218.
16. Miro O, Lopez S, Pedrol E, Rodriguez-Santiago B, Martinez E, Soler A, Milinkovic A, Casademont J, Nunes V, Gatell JM & Cardellach F. Mitochondrial DNA depletion and respiratory chain enzyme deficiencies are present in peripheral blood mononuclear cells of HIV-infected patients with HAART-related lipodystrophy. Antiviral Therapy 2003; 8:333-338.
17. Pol S, Carrat F, Hor TR, Deshayes J, Banisadr F, Rosenthal E & Perronne C. High risk of mitochondriopathy in HIV/HCV co-infected patients under concomitant ddI/d4T and interferon (standard and pegylated IFN)/ribavirin treatments. 38th Annual Meeting of the European Association of the Study of the Liver. 3-6 July 2003, Geneva, Switzerland. Abstract 3530.00.
18. Ballesteros AL, Franco S, Fuster D, Planas R, Martinez MA, Acosta L, Sirera G, Salas A, Tor J, Rey-Joly C, Clotet B & Tural C. Early HCV dynamics on peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS 2004; 18:59-66.
19. Miró O, Casademont J, Barrientos A, Urbano-Márquez A & Cardellach F. Mitochondrial cytochrome c oxydase inhibition during acute carbon monoxide poisoning. Pharmacology & Toxicology 1998; 82:199-202.
20. Barrientos A. In vivo and in organello assessment of OXPHOS activities. Methods 2002; 26:307-316.
21. López S, Miró O, Martínez E, Pedrol E, Rodríguez-Santiago B, Milinkovic A, Soler A, García-Viejo MA, Núñez V, Casademont J, Gatell JM & Cardellach F. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antiviral Therapy 2004; 9:47-55.
22. Carr A, Emery S, Law M, Puls R, Lundgren JD & Powderly WG; HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-735.
23. Walker UA, Setzer B & Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16:2165-2173.
24. Brinkman K, Smeitink JA, Romijn JA & Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
25. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA & Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735-1744.
26. White AJ. Mitochondrial toxicity and HIV therapy. Sexually Transmitted Infections 2001; 77:158-173.
27. Nolan D, Hammond E, James I, McKinnon E & Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antiviral Therapy 2003; 8:617-626.
28. Moreno A, Quereda C, Moreno L, Pérez-Elias MJ, Muriel A, Casado JL, Antela A, Dronda F, Navas E, Bárcena R & Moreno S. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antiviral Therapy 2004; 9:133-138.
29. Klein MB, Campeol N, Lalonde RG, Brenner B & Wainberg MA. Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. AIDS 2003; 17:1001-1008.
30. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ & Mallal SA. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001; 15:717-723.
31. Moyle GJ, Datta D, Mandaha S, Morlese J, Asboe D & Gazzard BG. Hyperlactatemia and lactic acidosis during antiretroviral therapy, relevance, reproducibility and possible risk factors. AIDS 2002; 16:1341-1349.
32. Brinkmann K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 2001; 15:795-797.
33. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, Boggian K, Chave JP, Bernasconi E, Egger M, Opravil M, Rickenbach M, Francioli P & Telenti A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV cohort study. Clinical Infectious Diseases 2001; 33:1931-1937.
34. Walker UA, Bäuerle J, Laguno M, Murillas J, Mauss S, Schmutz G, Setzer B, Miquel R, Gatell JM & Mallolas J. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39:311-317.
35. Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, Solsky J, Torriani FJ, Dieterich D & Larrey D. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18:F21-F25.
36. Cossarizza A & Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004; 18:137-151.
37. Lonergan JT, Behling C, Pfander H, Hassanein TI & Mathews C. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clinical Infectious Diseases 2000; 31:162-166.
38. Mirshahi F, Campbell-Sargent C, Sterling RK, Luketic VA, Shiffman M, Stravitz RT & Sanyal A. Non-alcoholic steatohepatitis (NASH) is associated with hepatocytes mitochondrial DNA depletion. Hepatology 2002; 36:403A.
39. Zaera MG, Miró O, Pedrol E, Soler A, Picón M, Cardellach F, Casademont J & Nunes V. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS 2001; 15:1643-1651.
40. Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S & Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15:1801-1809.
41. Brau N. Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy. AIDS 2003; 17:2279-2290.